Company’s 36-month beta value is 1.28.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HBIO is 39.97M, and currently, short sellers hold a 1.00% ratio of that floaft. The average trading volume of HBIO on November 15, 2024 was 119.70K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HBIO) stock’s latest price update
Harvard Bioscience Inc (NASDAQ: HBIO)’s stock price has soared by 5.53 in relation to previous closing price of 2.17. Nevertheless, the company has seen a loss of -4.18% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-09 that Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn – Corporate Controller James Green – Chairman, President and CEO Jennifer Cote – CFO Conference Call Participants Paul Knight – KeyBanc Bruce Jackson – The Benchmark Company Operator Good day, and welcome to the Third Quarter 2024 Harvard Biosciences Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
HBIO’s Market Performance
Harvard Bioscience Inc (HBIO) has experienced a -4.18% fall in stock performance for the past week, with a -6.15% drop in the past month, and a -22.37% drop in the past quarter. The volatility ratio for the week is 7.99%, and the volatility levels for the past 30 days are at 5.61% for HBIO. The simple moving average for the past 20 days is -4.70% for HBIO’s stock, with a -31.16% simple moving average for the past 200 days.
Analysts’ Opinion of HBIO
Many brokerage firms have already submitted their reports for HBIO stocks, with The Benchmark Company repeating the rating for HBIO by listing it as a “Buy.” The predicted price for HBIO in the upcoming period, according to The Benchmark Company is $4 based on the research report published on March 10, 2023 of the previous year 2023.
Northland Capital gave a rating of “Outperform” to HBIO, setting the target price at $6 in the report published on December 09th of the previous year.
HBIO Trading at -9.71% from the 50-Day Moving Average
After a stumble in the market that brought HBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.81% of loss for the given period.
Volatility was left at 5.61%, however, over the last 30 days, the volatility rate increased by 7.99%, as shares sank -4.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.12% lower at present.
During the last 5 trading sessions, HBIO fell by -4.18%, which changed the moving average for the period of 200-days by -47.95% in comparison to the 20-day moving average, which settled at $2.40. In addition, Harvard Bioscience Inc saw -57.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HBIO starting from Green James W, who purchase 10,000 shares at the price of $2.91 back on Jun 13 ’24. After this action, Green James W now owns 3,111,091 shares of Harvard Bioscience Inc, valued at $29,100 using the latest closing price.
Green James W, the Chief Executive Officer of Harvard Bioscience Inc, purchase 20,000 shares at $3.07 during a trade that took place back on Jun 06 ’24, which means that Green James W is holding 3,101,091 shares at $61,400 based on the most recent closing price.
Stock Fundamentals for HBIO
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.54 for the gross margin
The net margin for Harvard Bioscience Inc stands at -0.15. The total capital return value is set at -0.04. Equity return is now at value -20.40, with -10.51 for asset returns.
Based on Harvard Bioscience Inc (HBIO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -3.29.
Currently, EBITDA for the company is 9.49 million with net debt to EBITDA at -8.57. When we switch over and look at the enterprise to sales, we see a ratio of 1.33. The receivables turnover for the company is 7.62for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.06.
Conclusion
In a nutshell, Harvard Bioscience Inc (HBIO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
